November 29, 2018 10:06 AM EST

Boehringer axes biosimilar development outside US; MacroGenics, China's Zai Labs join forces to develop I/O treatments

ENDPOINTS

→ Germany’s Boehringer has elected to wash its hands off biosimilar development outside the United States. The decision likely comes in reaction to the painful …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Boehringer axes biosimilar development outside US; MacroGenics, China's Zai Labs join forces to develop I/O treatments

ENDPOINTS

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

AstraZeneca details its oral SERD 'switching' regimen as feasibility questions remain

Takeda, Protagonist unveil plenary data for potential blockbuster rare blood disease drug

As life-saving checkpoint drugs move to earlier cancers, researchers debate how best to use them

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Boehringer ax­es biosim­i­lar de­vel­op­ment out­side US; Macro­Gen­ics, Chi­na's Zai Labs join forces to de­vel­op I/O treat­ments

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Boehringer axes biosimilar development outside US; MacroGenics, China's Zai Labs join forces to develop I/O treatments